ERBB2 and breast cancer: Unlike HER2-positive breast cancer, which is also highly aggressive but benefits from targeted therapies like Trastuzumab deruxtecan (T-DXd) that have significantly improved outcomes, TNBC remains a major clinical challenge due to its heterogeneity, high recurrence rates, and poor prognosis.